GotReceipts tracks public buy and sell signals for Novo Nordisk (NVO)
and measures outcomes over matched windows.
For this ticker model, performance vs the S&P 500 is based on BUY/ADD calls only.
SELL/REDUCE calls are graded directionally and shown as Correct, Incorrect, or Pending.
That way, you can quickly see whether following public buy calls added value versus simply holding the index.
Do NVO stock predictions beat the S&P 500?
No. Across 2 scored BUY/ADD calls, average return is -26.7% versus +32.0% for the S&P 500, for -58.7% alpha.
Who has the best track record predicting Novo Nordisk?
Noel Quinn currently ranks #1 on NVO, with +6.8% average buy return versus +6.9% for the S&P 500 (-0.1% alpha) across 1 scored buy calls.
Is NVO overvalued or undervalued?
Public prediction track records currently lean cautious on NVO: buy calls have underperformed the index by +58.7% on average.
Should I follow analyst ratings on NVO?
Use analyst and public-figure calls as one input, not a standalone signal. GotReceipts shows historical outcomes versus the S&P 500 so you can judge signal quality before acting.